In the last two decades, great progress has been achieved in the cure of Hodgkin's disease. Nevertheless, about 30% of patients are still refractory to initial treatment and are candidates for alternative approaches (Santoro and Valagussa, 1992) . Several patient characteristics and clinical features have been correlated with disease outcome, in an attempt to identify the group of patients at high risk of lymphoma progression who might benefit from more intensified treatment approaches at the time of initial diagnosis, as well as those who can be managed with less intensive therapy to minimize iatrogenic sequelae.
From the clinical point of view, the prognostic factors most widely evaluated are related to tumour burden, including stage, number of involved sites, extranodal extent, bulky disease, extent of splenic involvement, systemic symptoms and pulmonary hilus involvement. In multivariate analyses, however, no single factor proved to offer independent prognostic information (Specht et al, 1988; Straus et al, 1990; Proctor et al, 1992) . In contrast, only a few studies have been carried out to establish the prognostic significance of host immune status-related factors.
Recently, the prognostic value of various immunological factors has been investigated, based on the evidence of the well-known defect in cell-mediated immunological reactions in patients with Hodgkin's disease, in particular with advanced stage and/or in the presence of systemic symptoms (Romagnani et al, 1985; Gause et al, 1992a; Clerici et al, 1994) . Several cytokines and soluble forms of cell-surface antigens of lymphocytes and Reed-Steinberg (RS) cells or reactive cells found in tissues involved by Hodgkin's disease, such as CD30, CD8 and CD25 have been evaluated. (Rubin et al, 1985; Hsu and Hsu, 1990; Kretschmer et al, 1990; Pfreundschuh et al, 1990; Grimfors et al, 1991; Gause et al, 1992b) . Recent clinical studies suggest a prognostic value of the soluble form of interleukin-2 receptor (IL-2R) Pui et al, 1989b; Gause et al, 1991 Gause et al, , 1992a Enblad et al, 1995) . IL-2R is expressed on the Hodgkin's disease and RS cells; moreover the malignant cells and Hodgkin's disease-RS-derived cell lines, when cultured in vitro, release to the supernatant a soluble form, the so-called soluble interleukin-2 receptor (sIL-2R) (Rubin and Nelson, 1990) . It consists of the p55 fragment of the whole IL-2 cell-surface receptor. The sIL-2R proved to be also released into the blood. Even though its affinity for circulating IL-2 is lower than that for the whole cell-surface receptor, sIL-2R has retained its ability to bind circulating IL-2 (Rubin et al, 1986) . Soluble IL-2R can determine a diminished IL-2 biological availability and can consequently be involved in the impaired T-cell function described in Hodgkin's disease patients (Gooding et al, 1995) . This compromised host's anti-tumour immunity could lead to unusually aggressive disease. In fact, abnormally high blood levels of sIL-2R have been detected in several clinical states characterized by suppression of cellular immunity, including AIDS and metastatic solid tumours (Kloster et al, 1987; Rovelli et al, 1988) . Moreover, recent clinical studies have also pointed out that elevated sIL-2R levels play a negative prognostic role in various malignancies, such as metastatic solid tumours, hairy cell leukaemia, chronic leukaemia, acute lymphoblastic leukaemia and lymphomas Semenzato et al, 1987; Pui et al, 1988a Pui et al, , 1989 Rovelli et al, 1988; Steis et al, 1988; Chilosi et al, 1989; Motoi et al, 1989; Gause et al, 1992a; Enblad et al, 1995) .
The aim of this study was to evaluate the correlation of sIL-2R levels in Hodgkin's disease patients with established factors known to influence clinical outcome, namely stage, B-symptoms, number of involved sites, bulky disease and extranodal extent. In addition, we investigated the prognostic role of sIL-2R and whether its levels measured after treatment and during follow-up could be used as a serum marker that is readily accessible, objective and easily evaluable to predict lymphoma reappearance. Patients were staged according to the Ann Arbor classification reviewed at Costwold (Lister et al, 1989 Table 2 . Patients in PS IA were treated with subtotal nodal radiotherapy (STNI); until June 1990 patients in PS IIA were also treated with STNI; from July 1990 patients in PS IB and IIA were given four cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by involved-field or subtotal nodal radiotherapy (RT). Patients with PS IIB, III and IV were treated with MOPP (mechlorethamine, vincristine, procarbazine and prednisone) alternated with ABVD for eight cycles followed by RT on the bulky site(s) of disease. From July 1990, these patient subgroups were given eight cycles of VEBEP (etoposide, epidoxorubicin, bleomycin, cyclophosphamide and prednisone) followed by involved-field RT at a median dose of 30 Gy.
PATIENTS AND METHODS Patients

Soluble IL-2 receptors
To evaluate serum levels of sIL-2R, venous blood samples were drawn from 174 patients immediately before the start of treatment, from 137 patients within 1 month after completion of therapy and from 132 patients during follow-up at different time intervals. The sera were stored in -20°C, coded and tested blindly. Serum sIL-2R were determined by the commercially available sandwich Elisa test kit (T-cell Sciences, Cambridge, MA, USA). Samples were assayed in duplicate. The sera of 65 healthy subjects with similar median and age range served as controls.
Statistical methods
Differences in the mean values of sIL-2R in the various patient subgroups were calculated using the t-test. When follow-up sera were assessed, the t-test for paired values was used. Freedom from progression (FFP) was calculated from the date of starting treatment to the first evidence of disease progression. The pattern of FFP was estimated by means of the product-limit method (Kaplan-Meier) (Kaplan and Meier, 1958) . The role of potentially significant prognostic factors on FFP was investigated in univariate analysis using a Cox regression model (Cox, 1972) . In this model, each regression coefficient (0) is the logarithm of the hazard ratio (HR), which is assumed constant in time. Under the null hypothesis that a variable has no prognostic role on FFP, HR is expected to be 1.00. The hypothesis of HR = 1.00 was tested using the Wald statistic. The sIL-2R serum level was analysed as continuous variable. The relationship between sIL-2R levels and FFP was investigated by resorting to a regression model based on restricted cubic splines. The most complex model considered was a four-nodes cubic spline with nodes located at the quartiles of the distribution of the sIL-2R (Durrleman and Simon, 1989) . The contribution of non-linear terms was evaluated by the likelihood ratio test. As sIL-2R was used as continuous variable, the values of HR concerning the unitary increment were not adequately informative. Therefore, we present the results related to an increment of 1000 U m1'. In order to allow the reader to calculate HR for each sIL-2R increase, we provide the regression coefficient estimates (0) from which it is possible to obtain HR value for each sIL-2R increase. CR, complete remission; FFP, freedom from progression.
RESULTS
Pretreatment sera
The mean sIL-2R level in patients with newly diagnosed untreated Hodgkin's disease was 1842 U ml-' and ranged from 321 to 10 770 U ml-', while in normal controls they were significantly lower ranging from 295 to 760 U ml-', with a mean value of 420 U ml-' (P < 0.0001).
The relation between main patient characteristics and sIL-2R levels is reported in Table 3 . Patients with B symptoms, more than three involved sites and advanced stage (stages III and IV) had significantly higher levels than their counterparts. Also, the small fraction of patients with extranodal extent had mean levels superior to those detected in patients presenting with nodal involvement alone. No significant relations were found when gender, age groups and histopathological subgroups were considered.
As illustrated in Figure 1 , a linear relationship between the logarithm of hazard and sIL-2R serum values was detected. Univariate analyses showed that sIL-2R levels were unable to significantly influence (at conventional 5% level) the 5-year FFP ( = 0.000153, HR = 1.16, 95% confidence interval 1.15-1.18, P 0.067). The most important factors able to influence FFP were the presence of systemic symptoms (presence vs absence of systemic symptoms: HR = 2.34, 95% confidence interval 1.04-5.25, P = 0.039) and the extent of disease expressed by number of involved sites (> vs < three involved sites: HR = 2.37, 95% confidence interval 1.07-5.22, P 0.032).
Post-therapy sera Soluble IL-2 receptors were also evaluated in 137 out of 174 patients immediately after the end of the entire treatment plan; 135 patients achieved complete remission (CR), one patient achieved only a partial remission (PR) and one showed lymphoma progression. The mean values of patients achieving CR were significantly lower than those observed at diagnosis (635 ± 19 vs 1795 ± 122, P = 0.0001). However, values within the normal range, i.e. < 500 U ml-', were observed in only 41 out of 135 (30%) patients achieving CR.
Follow-up sera
Soluble IL-2R serum levels were determined at least once in 132 out of the 135 patients who were in CR at the end of treatment. They remained low in the 114 patients who were in continuous CR (429.5±40.4) after a median of 56 months from the end of all therapies, while an increase was observed in 9 out of 12 (75%) patients who showed disease relapse after a median of 16 months (range values, had a similar disease recurrence rate (10%) compared with the group of 94 patients with sIL-2R levels above normal range at CR (8.5%). When the mean values of sIL-2R, measured before and at the end of therapy in patients who relapsed, were compared with those measured in patients who remained in CR, no difference could be detected, as reported in Table 5 . A temporary increase of sIL-2R was observed in six patients who are still in continuous CR. This increase was due to intercurrent infections in two cases, radiation pneumonitis in one case, hyperplastic adenopathies in one case and undetermined reasons in the remaining two patients. The median degree of increased levels with respect to the values observed at the previous control was of 105.5% (range 21-239%), and the median time from observation of sIL-2R increase to last follow-up was 67 months (range 44-78 months).
DISCUSSION
The findings of our study are in line with data reported by other investigators Pui et al, 1989a; Gause et al, 1991, 1992a and Enblad et al, 1995; Gorschluter et al, 1995 (Pui et al, 1989b; Grimfors et al, 1991; Gause et al, 1992b; Kurzrock et al, 1993; Blay et al, 1994; Triimper et al, 1994; Gorschluter et al, 1995) . In particular increased sCD8 and sCD30 have been demonstrated to be associated with a poor prognosis, even though only sCD30 seem to be strictly correlated with disease activity (Pui et al, 1989b; Grimfors et al, 1991; Gause et al, 1992a) . In addition, significant correlations were reported either between sCD30 and sIL-2R levels or between sCD8 and sIL-2R serum levels (Gause et al, 1992a) .
As far as interleukin levels are concerned, abnormally high blood concentrations of IL-6, IL-7 and IL-8 have been generally described in Hodgkin's disease, whereas IL-1, IL-2, IL-3 and IL-4 are rarely detectable (Gause et al, 1992b; Kurzrock et al, 1993; Blay et al, 1994; Trumper et al, 1994; Gorschluiter et al, 1995) .
In order to confirm previous results and to better understand the cytokine network involved in immunodeficiency related to Hodgkin's disease, we continue to evaluate in our case series sIL-2R, and we have also planned to simultaneously detect IL-2 and IL-I 2, the two main anti-tumour cytokines in humans, as well as IL-6 and IL-1O, which play an important role in inducing immunosuppression (Wanebo et al, 1986; Matsuda and Hirano, 1990; Howard and O'Garra, 1992; Banks et al, 1995) .
In conclusion, the results of the present study confirm that sIL-2R values correlate with disease spread and represent a host immune status-related factor associated with disease outcome, as with other conventional clinical prognostic factors. Therefore, their inclusion in the clinical evaluation should be taken into consideration, with the aim to have an additional guide for treatment decisions at initial diagnosis or during the follow-up. 
